Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (RFA-NS-26-001)
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required): (RFA-NS-26-001). Dated 184 days ago, it serves as a historical benchmark. Score 68/100. As of 2026-11-03, from Grants.gov (U.S. Department of Health and Human Services).
Data as of · Compiled by Zalwin from Grants.gov (U.S. Department of Health and Human Services)
Free preview: all 15 published fields of this record are shown below. Locked: 111 related GrantPulse records and the 5-column CSV export.
| Field | Value |
|---|---|
| Opportunity number | RFA-NS-26-001 |
| Title | Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) |
| Agency | National Institutes of Health |
| Status | posted |
| Posted / open date | 2026-05-04 |
| Close date | 2026-11-10 |
| Award ceiling | n/a |
| Award floor | n/a |
| Estimated total funding | $40,000,000 |
| Funding category | Health |
| Eligible applicants | City or township governments; For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Public housing authorities/Indian housing authorities; Native American tribal governments (Federally recognized); County governments; State governments; Special district governments; Independent school districts; Native American tribal organizations (other than Federally recognized tribal governments); Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Public and State controlled institutions of higher education |
| Eligibility notes | Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to support a marketing application) supported by a small business concern that is the FDA-designated sponsor of a drug or biological product which is |
| CFDA / Assistance listing | 93.853 |
| Summary | The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS. |
| Agency contact | [email protected] |
| Peer records CSV (112 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) + all 112 records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Opportunity · Agency · Status · Award ceiling · Closes · official source URL
- Source agency: Grants.gov (U.S. Department of Health and Human Services)
- Record date: 2026-05-04
- Data refreshed: 2026-11-03
- Refunds on request within 14 days
Top GrantPulse records (HHS first): Children’s Hospitals Graduate Medical Education (CHGME · Centers of Excellence in Healthcare Quality and Safety (CDC- · Title X Family Planning Services Grants (PA-FPH-27-001) · Development of Collaborative Research Facilities or Research · Emerging Infections Network - Research for Preventing, Detec · Browse all by state and category →
LIVE PUBLIC DATA Source: Grants.gov (U.S. Department of Health and Human Services) · Last refreshed: Tue, 03 Nov 2026 18:08:06 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) and 112 HHS peers
- HHS GrantPulse records like this one: 112
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every HHS peer: $22,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
68 / 100 Plain-English Eligibility Score
- Small businesses are listed as eligible applicants.
- Nonprofits are listed as eligible applicants.
- Only 6 days until the deadline.
What is the GrantPulse record for Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)?
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (RFA-NS-26-001) from National Institutes of Health: posted, award ceiling n/a.
How does Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) compare to other GrantPulse records?
It is 184 days old; check the official source for later updates before acting.
Get the readiness pack for this opportunity ($4.99)
Eligibility summary, registrations checklist, deadline timeline and a proposal outline, generated from this notice.
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) vs. top 3 peers
| Organization | Location | Combined award ceilings | Percentile | Record date |
|---|---|---|---|---|
| Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) | HHS | 2026-05-04 | ||
| Rural Communities Opioid Response Program - Overdose Response | HHS | $300,000 | 19th | 2026-08-21 |
| Rural Communities Opioid Response Program - Child and Adolescent Behavioral Health | HHS | $1,000,000 | 59th | 2026-08-21 |
| Rural Communities Opioid Response Program - Community Systems Development | HHS | $500,000 | 35th | 2026-08-14 |
Related records
- Rural Communities Opioid Response Program - Overdose Response
- Rural Communities Opioid Response Program - Child and Adolescent Behavioral Health
- Rural Communities Opioid Response Program - Community Systems Development
- Healthy Tomorrows Partnership for Children Program (HTPCP)
- Rural Residency Planning and Development Program
- Rural Health Value Program
- The National Network of STI Prevention Training Centers (NNPTC)
- Comprehensive Suicide Prevention Program for States
- NIOSH Small Research Grant Program (R03)
- NIOSH National Center of Excellence for the Prevention of Childhood Agricultural Injury (U54)
- Research Grants to Rigorously Evaluate Innovative and Promising Approaches to Prevent Firearm-Related Violence and Injuries
- Cooperative Research Agreements Related to the World Trade Center Health Program (U01)
Open and upcoming HHS federal grants Open and upcoming federal grants: Health
How to monitor Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) and peer health records
Get new GrantPulse records like Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new grants that fit you every week
GrantPulse emails new and forecasted grants matching your organization type and focus areas.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
Data from Grants.gov. Always read the full notice of funding opportunity before applying. Informational only; not legal or grant-writing advice.
Often used together
- FormDPulse
- NsfAwardPulse
- Public Works Prevailing Wage Intent + Environmental Remediation & Tank Retrofit Multi-Signal Trigger
- ContentVelocityRadar
- B2BDomainSignalVerify
- PodcastSponsorRadar
Or get the Advisor Prospecting Bundle for $14.99 one-time: Full CSV unlock of newly funded companies plus a grant readiness pack.